Clinical trial
Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
NCT00131274 · Daniels, Craig E., M.D., Other · Completed
Key facts
| NCT number | NCT00131274 |
|---|---|
| Title | Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study |
| Official title | A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis |
| Lead sponsor | Daniels, Craig E., M.D., Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Idiopathic Pulmonary Fibrosis, Lung Disease, Pulmonary Fibrosis |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate (Gleevec) |
| Enrollment | 120 |
| Start date | Apr 1, 2003 |
| Completion | Aug 1, 2007 |
| First posted | Aug 18, 2005 |
| Last update posted | Oct 5, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: